https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-732009-10-27 00:00:002021-11-15 14:45:35Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-14 / Biol. Blood Marrow Transplant. 2010 Mar;16(3):320-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-14 / Biol. Blood Marrow Transplant. 2010 Mar;16(3):320-322009-10-14 00:00:002019-02-15 08:50:56Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-302009-10-13 00:00:002009-10-13 00:00:00Oncolytic virus therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-842009-10-06 00:00:002009-10-06 00:00:00Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Melanoma Res. 2009 Oct;19(5):309-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Melanoma Res. 2009 Oct;19(5):309-152009-10-01 00:00:002019-02-15 08:49:26Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Breast 2009 Oct;18 Suppl 3:S51-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Breast 2009 Oct;18 Suppl 3:S51-42009-10-01 00:00:002019-02-15 08:50:12Immunizing against breast cancer: a new swing for an old sword
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-7122009-10-01 00:00:002021-11-15 14:46:05Dendritic cell therapy of high-grade gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Brain Pathol. 2009 Oct;19(4):674-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Brain Pathol. 2009 Oct;19(4):674-932009-10-01 00:00:002019-02-15 08:59:39Immunotherapy of diffuse gliomas: biological background, current status and future developments
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Mol. Cancer Ther. 2009 Oct;8(10):2773-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Mol. Cancer Ther. 2009 Oct;8(10):2773-92009-10-01 00:00:002019-02-15 08:59:38An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Hum. Gene Ther. 2009 Oct;20(10):1106-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Hum. Gene Ther. 2009 Oct;20(10):1106-182009-10-01 00:00:002019-02-15 08:44:11Dendritic cell-based cancer gene therapy
